Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free SCNI Stock Alerts
Live Earnings Conference Call: Scinai Immunotherapeutics will host a live Q2 2026 earnings call on August 26, 2026 at 11:00AM ET. Follow this link to get details and listen to Scinai Immunotherapeutics' Q2 2026 earnings call when it goes live. Get details.

Scinai Immunotherapeutics (SCNI) Financials

Scinai Immunotherapeutics logo
$2.88 -0.25 (-7.99%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$2.96 +0.08 (+2.60%)
As of 08/25/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Scinai Immunotherapeutics

Annual Income Statements for Scinai Immunotherapeutics

This table shows Scinai Immunotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.00 -35 -120 -329 -377 -1.38 -8.21 -5.80 -6.50 4.80 -8.31
Consolidated Net Income / (Loss)		 0.00 -35 -120 -329 -377 -1.38 -8.21 -5.80 -6.50 4.80 -8.31
Net Income / (Loss) Continuing Operations		 0.00 -35 -120 -329 -377 -1.38 -8.21 -5.80 -6.49 4.80 -8.31
Total Pre-Tax Income 		0.00 -35 -120 -329 -377 -1.38 -8.21 -5.80 -6.49 4.80 -8.31
Total Operating Income		 0.00 -46 -82 -289 -271 -21 -11 -11 -9.71 -8.64 -7.54
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.58 -2.65
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.66 1.31
Operating Revenue		 - 0.00 0.00 - - - - 0.00 0.00 0.66 1.31
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.24 3.96
Operating Cost of Revenue		 - - - - - - - 0.00 0.00 1.24 3.96
Total Operating Expenses		 0.00 46 82 289 271 21 11 11 9.72 8.06 4.89
Selling, General & Admin Expense		 0.00 16 17 19 34 5.19 7.63 5.30 4.51 2.53 2.52
Research & Development Expense		 0.00 30 65 270 237 16 3.25 5.77 5.21 5.53 2.37
Total Other Income / (Expense), net		 0.00 10 -38 -40 -107 20 2.67 5.27 3.22 13 -0.77
Interest Expense		 0.00 1.17 38 51 107 4.86 - 0.00 0.00 -15 0.00
Interest & Investment Income		 - 12 0.06 11 0.01 1.19 2.66 - 0.01 0.00 0.00
Other Income / (Expense), net		 - -0.02 -0.02 0.00 0.00 23 0.01 5.27 3.21 -1.33 -0.77
Basic Earnings per Share		 - ($0.07) ($0.17) ($0.34) ($0.33) ($0.01) ($0.02) $0.01 $0.00 $0.00 $0.00
Weighted Average Basic Shares Outstanding		 105.52M 135.10M 201.03M 261.42M 326.65M 443.26M 564.58M 1.31B 1.86B 3.41B 13.87B
Diluted Earnings per Share		 - ($0.07) ($0.17) ($0.34) - - - $0.01 $0.00 $0.00 $0.00
Weighted Average Diluted Shares Outstanding		 105.52M 135.10M 201.03M 261.42M 326.65M 443.26M 564.58M 754.08M 1.56B 3.23B 9.34B
Weighted Average Basic & Diluted Shares Outstanding		 105.52M 135.10M 201.03M 261.42M 326.65M 443.26M 564.58M 1.31B 1.86B 3.41B 13.87B

Quarterly Income Statements for Scinai Immunotherapeutics

No quarterly income statements for Scinai Immunotherapeutics are available.

Annual Cash Flow Statements for Scinai Immunotherapeutics

This table details how cash moves in and out of Scinai Immunotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.00 -68 167 -197 -278 4.15 14 -3.30 -9.21 -2.92 -0.28
Net Cash From Operating Activities		 0.00 -37 -24 -268 -326 6.01 -7.43 -7.27 -9.38 -6.34 -6.03
Net Cash From Continuing Operating Activities		 0.00 -36 -24 -268 -326 6.01 -7.43 -7.27 -9.38 -6.34 -6.03
Net Income / (Loss) Continuing Operations		 0.00 -35 -120 -329 -377 -1.38 -8.21 -5.80 -6.50 4.80 -8.31
Consolidated Net Income / (Loss)		 0.00 -35 -120 -329 -377 -1.38 -8.21 -5.80 -6.50 4.80 -8.31
Depreciation Expense		 0.00 2.39 1.53 0.97 5.69 0.76 0.47 0.56 0.51 1.65 1.42
Non-Cash Adjustments To Reconcile Net Income		 0.00 -5.59 76 -7.69 56 11 -0.55 -2.46 -2.66 -13 0.69
Changes in Operating Assets and Liabilities, net		 0.00 2.32 18 68 -10 -4.71 0.85 0.43 -0.74 0.43 0.16
Net Cash From Investing Activities		 0.00 -30 -1.53 -88 -25 -1.86 -0.14 -0.84 -0.64 -0.01 -0.02
Net Cash From Continuing Investing Activities		 0.00 -30 -1.53 -88 -26 -1.86 -0.14 -0.84 -0.64 -0.01 -0.02
Purchase of Property, Plant & Equipment		 0.00 -0.08 - -89 -26 - -0.14 -0.84 -0.64 -0.01 -0.02
Net Cash From Financing Activities		 0.00 0.00 193 316 294 0.00 21 6.78 1.09 3.44 5.77
Net Cash From Continuing Financing Activities		 0.00 0.00 193 316 296 0.00 21 6.78 1.09 3.44 5.77
Issuance of Common Equity		 - - 193 0.00 243 0.00 21 0.93 0.14 2.00 5.77
Other Financing Activities, net		 - - 0.06 0.00 0.00 - - 5.84 0.95 1.44 0.00
Cash Interest Paid		 - - 0.25 0.17 0.45 0.01 0.00 0.92 0.83 0.14 0.00

Quarterly Cash Flow Statements for Scinai Immunotherapeutics

No quarterly cash flow statements for Scinai Immunotherapeutics are available.

Annual Balance Sheets for Scinai Immunotherapeutics

This table presents Scinai Immunotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.00 283 397 400 18 32 27 17 13 12
Total Current Assets		 0.00 247 288 253 3.30 18 14 5.45 2.39 2.05
Cash & Equivalents		 4.53 247 284 - - 17 14 4.87 1.96 1.66
Restricted Cash		 - - - - - 0.14 0.14 0.14 0.13 0.15
Accounts Receivable		 0.00 - 3.62 - - - - 0.00 0.08 0.07
Prepaid Expenses		 - - - - - - 0.16 0.44 0.21 0.17
Plant, Property, & Equipment, net		 0.00 19 106 0.00 0.00 12 11 11 9.19 7.79
Total Noncurrent Assets		 0.00 17 2.77 0.00 0.00 1.81 1.45 1.20 1.87 1.78
Other Noncurrent Operating Assets		 0.00 3.05 2.77 - - 1.81 1.45 1.20 1.87 1.78
Total Liabilities & Shareholders' Equity		 0.00 283 397 400 18 32 27 17 13 12
Total Liabilities		 0.00 683 78 625 22 3.52 29 22 3.47 3.52
Total Current Liabilities		 0.00 22 82 66 20 2.44 2.34 1.78 1.81 1.59
Accounts Payable		 0.00 22 78 - - 2.07 1.96 1.38 1.38 1.26
Other Current Liabilities		 - - 0.00 - - 0.00 0.38 0.40 0.42 0.33
Total Noncurrent Liabilities		 0.00 661 432 559 2.27 1.45 26 20 1.67 1.94
Long-Term Debt		 - - - - - - 20 19 0.26 0.29
Other Noncurrent Operating Liabilities		 - 661 0.00 - - 1.45 6.41 0.89 1.41 1.64
Commitments & Contingencies		 - - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.00 -400 -117 -225 -4.54 0.98 -1.76 -4.57 9.98 8.10
Total Preferred & Common Equity		 0.00 -400 -117 -225 -4.54 0.98 -1.76 -4.57 9.98 8.10
Preferred Stock		 0.00 - 674 - - - - 0.00 5.63 5.63
Total Common Equity		 0.00 -400 -791 -225 -4.54 0.98 -1.76 -4.57 4.35 2.48
Common Stock		 0.00 0.00 0.00 - - 113 116 120 124 130
Retained Earnings		 0.00 -428 -791 - - -110 -116 -122 -118 -126
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -2.06 -2.01 -1.74 -1.74 -1.74

Quarterly Balance Sheets for Scinai Immunotherapeutics

No quarterly balance sheets for Scinai Immunotherapeutics are available.

Annual Metrics And Ratios for Scinai Immunotherapeutics

This table displays calculated financial ratios and metrics derived from Scinai Immunotherapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 0.00 454,145,376.00 461,285,824.00 573,285,824.00 573,285,824.00 1,857,169,984.00 1,857,169,984.00 1,857,169,984.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 4,541,454.00 4,612,858.00 5,732,858.00 5,732,858.00 185,716,998.00 185,716,998.00 185,716,998.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 -83.10 -0.30 -1.43 -1.01 -0.04 0.03 -0.04
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 99.24%
EBITDA Growth		 0.00% 0.00% -85.55% -257.56% 7.91% 101.15% -442.15% 49.63% -14.37% -38.89% 17.18%
EBIT Growth		 0.00% 0.00% -79.20% -252.10% 6.25% 100.84% -576.45% 46.64% -12.15% -53.28% 16.62%
NOPAT Growth		 0.00% 0.00% -79.25% -252.19% 6.25% 92.18% 48.67% -1.72% 12.25% -27.14% 38.88%
Net Income Growth		 0.00% 0.00% -239.22% -174.48% -14.77% 99.63% -492.56% 29.37% -12.15% 173.78% -273.21%
EPS Growth		 0.00% 0.00% -142.86% -100.00% 0.00% 0.00% 0.00% 0.00% -12.15% -100.00% 0.00%
Operating Cash Flow Growth		 0.00% 0.00% 34.98% -1,010.51% -21.79% 101.84% -223.63% 2.17% -29.14% 32.48% 4.80%
Free Cash Flow Firm Growth		 0.00% 0.00% 1,940.86% -249.85% 82.43% 90.45% -23.34% 93.59% -964.79% 43.97% 46.74%
Invested Capital Growth		 0.00% 0.00% 0.00% 105.30% -100.00% 0.00% 0.00% -61.54% 138.35% -16.83% -19.11%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -88.15% -202.29%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,263.53% -525.25%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,312.77% -575.29%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,514.13% -633.64%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 728.88% -633.64%
Tax Burden Percent		 0.00% 99.93% 99.98% 100.00% 100.00% 100.00% 100.00% 100.00% 100.14% 100.00% 100.00%
Interest Burden Percent		 0.00% 77.19% 146.04% 113.83% 139.37% -60.74% 75.55% 100.00% 99.86% -48.14% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -96.35% -71.69%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 118.20% 108.95%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 273.71% -20.20%
Return on Equity (ROE)		 0.00% 0.00% 59.96% 127.31% 220.81% 1.21% 461.64% 1,489.97% 205.40% 177.37% -91.89%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -2,576.52% -905.54% 0.00% -342.57% -15.85% -179.57% -77.98% -50.56%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -64.44% -66.26%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.02% -66.26%
Return on Common Equity (ROCE)		 0.00% 0.00% 59.96% 293.53% 656.43% 1.21% 461.64% 1,489.97% 205.40% -7.18% -34.69%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 29.98% 281.04% 167.85% 30.52% -835.64% 329.32% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.00 -32 -57 -202 -190 -15 -7.61 -7.74 -6.79 -8.64 -5.28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,312.77% -402.70%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% -50.41% -263.23% 99.88% -11.72% 8.35% -25.02% -2.91% -214.55% -180.64%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -42.26% -45.91% -84.38% -62.87%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 188.15% 302.29%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 383.89% 192.30%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 840.73% 180.70%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,224.62% 373.00%
Earnings before Interest and Taxes (EBIT)		 0.00 -46 -82 -289 -271 2.28 -11 -5.80 -6.50 -9.96 -8.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.00 -43 -81 -288 -265 3.04 -10 -5.23 -5.99 -8.31 -6.89
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 27.60 0.00 0.00 3.57 1.34
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 27.60 0.00 0.00 3.57 1.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.60 2.52
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.24 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 30.88% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.90 2.46 3.46 2.37 1.13
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.37 5.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 10.51 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 13.99 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 5.31 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.41 -4.24 0.03 0.04
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.41 -4.24 0.03 0.04
Financial Leverage		 0.00 0.00 0.62 0.19 -1.10 -1.00 -4.00 -20.00 -3.20 2.32 -0.19
Leverage Ratio		 0.00 0.00 -0.71 -1.32 -2.33 -1.82 -13.99 -75.97 -7.04 5.72 1.39
Compound Leverage Factor		 0.00 0.00 -1.04 -1.50 -3.25 1.11 -10.57 -75.97 -7.03 -2.75 1.39
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 109.61% 130.87% 2.54% 3.50%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 109.61% 130.87% 2.54% 3.50%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% -576.42% 0.00% 0.00% 0.00% 0.00% 0.00% 54.97% 67.01%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 100.00% 676.42% 100.00% 100.00% 100.00% -9.61% -30.87% 42.49% 29.49%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.84 -3.24 -0.03 -0.04
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.12 -2.40 0.22 0.22
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.84 -3.24 -0.03 -0.04
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.59 -2.85 -0.03 -0.06
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.76 -2.11 0.21 0.29
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.59 -2.85 -0.03 -0.06
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 0.16 -0.72 -6.08 -10.25 -11.90 -16.79
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% -130.56% -197.29% 0.00% 0.00% 0.00% 0.00% 104.05% 62.25%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 0.00 11.47 3.53 3.86 0.17 7.30 6.15 3.06 1.32 1.30
Quick Ratio		 0.00 0.00 11.47 3.53 0.00 0.00 7.11 6.02 2.74 1.13 1.09
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -32 590 -884 -155 -15 -18 -1.17 -12 -6.99 -3.72
Operating Cash Flow to CapEx		 0.00% -48,265.00% -154.41% -303.07% -1,271.33% 323.58% -5,342.45% -869.02% -1,472.84% -52,791.67% -25,129.17%
Free Cash Flow to Firm to Interest Expense		 0.00 -27.49 15.58 -17.34 -1.46 -3.05 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -31.86 -0.64 -5.26 -3.06 1.24 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -31.92 -1.05 -6.99 -3.30 0.85 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.10
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 16.81
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.15
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.90 3.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.72
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 407.75 121.48
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -407.75 -99.77
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 0.00 -647 34 0.00 0.00 11 4.11 9.79 8.14 6.59
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.18
Increase / (Decrease) in Invested Capital		 0.00 0.00 -647 681 -34 0.00 11 -6.57 5.68 -1.65 -1.56
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 0.00 32 9.58 10 34 19 7.42
Market Capitalization		 0.00 0.00 0.00 0.00 0.00 32 27 4.24 20 16 3.31
Book Value per Share		 $0.00 $0.00 ($1.99) ($3.03) ($0.69) ($0.01) $0.00 $0.00 $0.00 $0.00 $0.00
Tangible Book Value per Share		 $0.00 $0.00 ($1.99) ($3.03) ($0.69) ($0.01) $0.00 $0.00 $0.00 $0.00 $0.00
Total Capital		 0.00 0.00 -400 -117 -225 -4.54 0.98 18 15 10 8.40
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20 19 0.26 0.29
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20 19 0.26 0.29
Net Debt		 0.00 -4.53 -247 -284 0.00 0.00 -18 5.87 14 -1.84 -1.52
Capital Expenditures (CapEx)		 0.00 0.08 16 88 26 1.86 0.14 0.84 0.64 0.01 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.53 -22 -78 187 -17 -2.12 -2.18 -1.34 -1.51 -1.34
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 226 206 187 -17 15 12 3.67 0.59 0.47
Net Working Capital (NWC)		 0.00 0.00 226 206 187 -17 15 12 3.67 0.59 0.47
Net Nonoperating Expense (NNE)		 0.00 3.28 62 127 188 -13 0.59 -1.95 -0.29 -13 3.03
Net Nonoperating Obligations (NNO)		 0.00 0.00 -247 151 225 4.54 9.70 5.87 14 -1.84 -1.52
Total Depreciation and Amortization (D&A)		 0.00 2.39 1.53 0.97 5.69 0.76 0.47 0.56 0.51 1.65 1.42
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -229.48% -102.36%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 88.91% 35.77%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 88.91% 35.77%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($3.40) ($3.30) ($0.03) ($0.20) ($0.10) ($0.04) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 45.41M 46.13M 57.33M 75.41M 156.26M 3.41B 13.87B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($3.40) ($3.30) ($0.03) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 45.41M 46.13M 57.33M 131.36M 185.72M 3.23B 9.34B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($3.40) ($3.30) ($0.03) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 20.10M 26.14M 32.67M 44.33M 56.46M 131.36M 185.72M 3.41B 13.87B
Normalized Net Operating Profit after Tax (NOPAT)		 0.00 -32 -57 -202 -190 -15 -7.61 -7.74 -6.79 -6.05 -5.28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -918.94% -402.70%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 728.88% -633.64%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -39.29 -2.17 -5.67 -2.54 0.47 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -27.49 -1.52 -3.97 -1.78 -3.05 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -39.36 -2.58 -7.40 -2.78 0.09 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -27.56 -1.93 -5.70 -2.02 -3.43 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Scinai Immunotherapeutics

No quarterly metrics and ratios for Scinai Immunotherapeutics are available.


Financials Breakdown Chart

Scinai Immunotherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Scinai Immunotherapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Scinai Immunotherapeutics' net income appears to be on a downward trend, with a most recent value of -$8.31 million in 2025, falling from $0.00 in 2015. The previous period was $4.80 million in 2024. View Scinai Immunotherapeutics' forecast to see where analysts expect Scinai Immunotherapeutics to go next.

Scinai Immunotherapeutics' total operating income in 2025 was -$7.54 million, based on the following breakdown:
  • Total Gross Profit: -$2.65 million
  • Total Operating Expenses: $4.89 million

Over the last 10 years, Scinai Immunotherapeutics' total revenue changed from $0.00 in 2015 to $1.31 million in 2025, a change of 131,100,000.0%.

Scinai Immunotherapeutics' total liabilities were at $3.52 million at the end of 2025, a 1.5% increase from 2024, and a 352,300,000.0% increase since 2016.

In the past 9 years, Scinai Immunotherapeutics' cash and equivalents has ranged from $0.00 in 2019 to $284.41 million in 2018, and is currently $1.66 million as of their latest financial filing in 2025.

Over the last 10 years, Scinai Immunotherapeutics' book value per share changed from 0.00 in 2015 to 0.00 in 2025, a change of 0.0%.


Related Companies

Financial statements for NASDAQ:SCNI last updated on 8/21/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
The New Kings of Cantillon
In 1720, Richard Cantillon discovered that new money never spreads evenly through an economy. It reaches certa...
Porter & Company | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel